My husband has the amplification of the pathway and was in the trial that used herceptin and perjeta. He was in the trial 8 months. The 2 lesions on the liver remained stable but the one on the abdominal wall grew 20% and forced him from the trial. He was another trial after that ,immunotherapy, which shrunk the tumor on the wall but the liver lesions grew. Currently on chemo gemcitabin and abraxane.
Hello My husband was diagnosed in May 2017 with recurrent cholangiocarcinoma. He was in a clinical trial that used herceptin and perjeta. He has am amplification of a pathway. He began in Nov. 2017. During the trial 2 tumors on the liver remained stable or slightly decreased however the one on the abdominal wall remained stable until a few months ago. By end July it had increased 20%. That excluded him from the trial. He tolerated the side effect fairly well. Fatigue and pain were the biggest side effect and lack of appetite . He is currently in a new trial, phase 1, using a brand new immunotherapy drug. It is a Bispecific DART Protein Binding PD-1 and LAG3. He is being treated at Johns Hopkins.